Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis.
Although preclinical animal studies have demonstrated the utility of recombinant human vascular endothelial growth factor (rhVEGF) in promoting neovascularization in regions of ischemia, rhVEGF systemic administration did not provide clinical benefit to patients in recent placebo-controlled Phase II clinical trials. The amount of rhVEGF localized in the ischemic region after systemic administration is minimal and does not persist for more than 1 day. A greater persistence of rhVEGF at the region of ischemia may provide an increased angiogenesis with the eventual formation of patent blood vessels to restore nourishment to the tissues. We sought to develop a formulation of rhVEGF in poly(D,L-lactide--co-glycolide) (PLG) microspheres that would provide a continuous local delivery of intact protein. A stable formulation of rhVEGF for encapsulation contained a small amount of a stabilizing sugar, trehalose. Addition of excess trehalose increased the rate of release from the PLG. In addition, PLG with free acid end groups appeared to retard the initial release of rhVEGF by associating with it through ionic interactions at the positively charged heparin binding domain. rhVEGF was released continuously for 21 days with a very low (less than 10%) initial burst. The released rhVEGF aggregated and hydrolyzed over time and lost heparin affinity but not receptor affinity. The compression molding of rhVEGF PLG microspheres into disks yielded formulations with a low initial release and a lag of 10 days followed by complete release. The PLG microsphere formulations were assessed in the corneal implant model of angiogenesis and generated a dose-dependent angiogenic response. These formulations were also administered intravitreally and subretinally, generating local neovascularization comparable to the human disease states, vitroretinopathy and age-related macular degeneration, respectively. The rhVEGF PLG formulations may increase local angiogenesis without systemic side effects and may also be useful in the development of ocular disease models.
Cleland
J L
JL
Department of Pharmaceutical R & D, Genentech, Inc., 1 DNA Way S., San Francisco, CA 94080, USA. cleland@gene.com
Duenas
E T
ET
Park
A
A
Daugherty
A
A
Kahn
J
J
Kowalski
J
J
Cuthbertson
A
A
D000818:Animals; D002846:Chromatography, Affinity; D002850:Chromatography, Gel; D003315:Cornea / Q000098:blood supply; D004337:Drug Carriers / Q000737:chemistry*; D016228:Endothelial Growth Factors / Q000008:administration & dosage* / Q000494:pharmacology*; D006493:Heparin / Q000737:chemistry; D019344:Lactic Acid / Q000737:chemistry*; D008222:Lymphokines / Q000008:administration & dosage* / Q000494:pharmacology*; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012995:Solubility; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D004337:Drug Carriers; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011108:Polymers; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D006493:Heparin